BriaCell Offers New Hope for Breast Cancer Patients
Company Announcements

BriaCell Offers New Hope for Breast Cancer Patients

Story Highlights

BriaCell Therapeutics (TSE:BCT) has released an update.

BriaCell Therapeutics has announced that the FDA has authorized an Expanded Access Policy allowing metastatic breast cancer patients to receive their novel Bria-IMT™ immunotherapy outside of the current Phase 3 clinical trial. This policy aims to provide additional treatment options for patients who have exhausted other therapies, with the hope of improving care for a disease that remains a leading cause of cancer death among American women.

For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskBriaCell Shows Promise in Cancer Immunotherapy Advances
TheFlyBriaCell reports preclinical data of personalized off-the-shelf immunotherapies
TipRanks Canadian Auto-Generated NewsdeskBriaCell Unveils Promising Cancer Therapy Data
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App